title: [Change in interferon status in patients with acute viral hepatitis during intramuscular and rectal administration of genetically engineered alpha-2-interferon].
abstract: Viferon500 suppositories representing a combination of recombinant alpha 2-interferon and membrane-stabilizing agents were used in the treatment of adult patients with acute viral hepatitis B. Changes in interferon status of the blood under the effect of reaferon and viferon500 were studied. Both reaferon and viferon500 suppositories were found to stimulate interferon synthesis in patients with acute viral hepatitis B, their stimulating effect correlating with the positive time course of clinical manifestations of the disease. The results permit us recommend viferon500 for the treatment of viral hepatitis in the early period of the icterus in order to prevent the disease progress. Parameters of the interferon system may serve as an objective criterion for assessment of the treatment efficacy.
authors.forename: V V
authors.initials: VV
authors.lastname: Malinovskaia
authors.forename: M V
authors.initials: MV
authors.lastname: Neumoina
authors.forename: S V
authors.initials: SV
authors.lastname: Budanov
mesh_terms: D000208:Acute Disease; D000285:Administration, Rectal; D000293:Adolescent; D000328:Adult; D006509:Hepatitis B / Q000097:blood / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007372:Interferons / Q000097:blood*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007372:Interferons